omniture
Ascentage Pharma

Latest News

Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-01-14 09:32 606

Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies

SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-01-05 08:32 971

Ascentage Pharma's Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment

SUZHOU, China and ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-12-22 18:29 556

Ascentage Pharma Announces Updates on the Clinical Development of APG-2575, including an ORR of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

SUZHOU, China and ROCKVILLE, MD, Dec. 10, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-12-10 09:03 698

Ascentage Pharma Appoints Mr. Gang Zhu as Chief Commercial Officer to Lead Commercial Initiatives

SUZHOU, China and ROCKVILLE, Md., Dec. 4, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-12-04 08:28 1119

Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology

SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-11-30 08:09 692

Ascentage Pharma Receives Approvals for Two Phase Ib/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenström Macroglobulinemia and Multiple Myeloma in China

SUZHOU, China and ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-11-23 18:32 660

Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China

SUZHOU, China and ROCKVILLE, Md., Oct. 21, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-10-21 17:37 968

Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA

SUZHOU, China and ROCKVILLE, MD., Oct. 9, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-10-09 08:21 1488

Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer

SUZHOU, China and ROCKVILLE, Md., Sept. 14, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-09-14 18:35 964

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia

SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-09-07 17:16 1320

Ascentage Pharma Releases Preclinical Results of IAP Antagonist APG-1387 in an Oral Presentation at EASL ILC 2020

SUZHOU, China and ROCKVILLE, Md., Aug. 27, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-08-27 18:10 3199

Ascentage Pharma Releases 2020 Interim Results, Reporting the Company's First New Drug Application and Advances in Global Strategic Collaborations

SUZHOU, China and ROCKVILLE, Md., Aug. 18, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-08-18 20:24 1733

Ascentage Pharma Becomes a Constituent of Three Major Indexes Including Hang Seng Composite Index

SUZHOU, China, and ROCKVILLE, MD., Aug. 17, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-08-17 07:30 1585
12